EUCTR2005-000447-28-DE进行中（未招募）不适用
EFFICACY AND SAFETY OF AMLODIPINE USED AS ADD-ON THERAPY IN MODERATELY TO SEVERELY HYPERTENSIVE PATIENTS NOT ADEQUATELY CONTROLLED BY OLMESARTAN MEDOXOMIL 20 MG MONOTHERAPY
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 429
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female patients at the age of 18 years or above with moderate to severe hypertension defined as a mean sitting sBP of 160 mmHg and a mean sitting dBP of 100 mmHg not on antihypertensive medication and a mean 24-hour dBP assessed by 24h-ABPM of at least 84 mmHg and with at least 30% of daytime dBP readings above 90 mmHg at Visit 2 (at the end of the taper-off period) will enter Period I.
- •Eligible patients who at Screening are already taking a stable dose of OM 20 mg or OM 40 mg for at least four weeks have to fulfil the following criteria before entering directly into Period I: previously suffered from moderate to severe hypertension (before first intake of OM 20 mg or OM 40 mg) mean sitting sBP 140 mmHg and mean sitting dBP 90 mmHg at Screening a mean 24-hour dBP of at least 80 mmHg assessed by 24h-ABPM and with at least 30% of daytime dBP readings over 85 mmHg.
- •To be randomised to Period II, the mean 24-hour dBP assessed by 24h-ABPM must be at least 80 mmHg and at least 30% of the daytime dBP readings must be above 85 mmHg. Furthermore, the overall mean trough sitting dBP must be between 90 mmHg and 115 mmHg inclusive and the overall mean trough sitting sBP must be 140 mmHg (at Visit 4/Week 8, conventional BP measurements).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Female patients of childbearing potential must not be pregnant or lactating. Female patients of childbearing potential must be using adequate contraception.
- •- Patients with serious disorders which may limit the ability to evaluate the efficacy or safety of the test drug(s), including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological or oncological, neurological and psychiatric diseases.
- •- Patients having a history of the following within the last six months: myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, congestive heart failure, hypertensive encephalopathy, cerebrovascular accident (stroke) or transient ischaemic attack.
- •- Patients with clinically significant elevations of laboratory values at Screening.
- •- Patients with secondary hypertension of any aetiology such as renal disease, pheochromocytoma or Cushing’s syndrome.
- •- Patients with contraindication to amlodipine and/or olmesartan medoxomil.
研究者
相似试验
进行中（未招募）
1 期
EFFICACY AND SAFETY OF AMLODIPINE USED AS ADD-ON THERAPY IN MODERATELY TO SEVERELY HYPERTENSIVE PATIENTS NOT ADEQUATELY CONTROLLED BY OLMESARTAN MEDOXOMIL 20 MG MONOTHERAPY. Eficacia y seguridad de amlodipino utilizado como terapìa adicional en pacientes con hipertensión moderada a severa no controlada adecuadamente con olmesartán medoxomilo 20 mg en monoterapiaessential hypertensionMedDRA version: 7.0Level: LLTClassification code 10015488EUCTR2005-000447-28-ESSankyo Pharma GmbH429
已完成
3 期
effects of amlodipine to reduce cardiac iron overloadMajor Thalasemia.Beta thalassemiaD56.1IRCT20190829044642N1Arak University of Medical Sciences30
已完成
不适用
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels (GEMINI-AALA)PER-010-04PFIZER S.A.,
已完成
不适用
Effect of combination therapy with amlodipine and atorvastatin on blood pressure varaiability, vascular function and renal function in hypertensive patients with chronic kidney diseaseHypertension with chronic kidney disease (CKD stage 1-4)JPRN-UMIN000009045Yokohama city university hospital50
尚未招募
Unknown
Comparative study to assess effectiveness and Safety of Amlodipine and Telmisartan.CTRI/2024/02/062389Dr Reddys Laboratories Ltd